Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer studyTogether, these two studies support the compelling potential of pelareorep-based combination therapy to benefit patients with advanced or metastatic HR+/HER2- breast cancerOncolytics Biotech is moving forward to secure funding for a registration-enabling study of pelareorep-based therapy in advanced or metastatic breast cancerOver half of BRACELET-1 patients in the pelareorep…
Read More…
Source: https://finance.yahoo.com/news/oncolytics-biotech-reports-favorable-results-110000958.html